◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

NurExone Biologic Inc.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Total Revenue 0.00 0.00 0.00 0.00 0.00 --
Operating Revenue 0.00 0.00 0.00 0.00 0.00 --
Selling General And Administration 763,000 1.1M 1.1M 822,000 782,000 --
General And Administrative Expense 763,000 1.1M 1.1M 822,000 782,000 --
Research And Development 703,000 697,000 618,000 632,000 503,000 --
Operating Expense 1.5M 1.8M 1.7M 1.5M 1.3M --
Operating Income -1.5M -1.8M -1.7M -1.5M -1.3M --
EBIT -1.4M -1.8M -1.7M -1.5M -1.2M --
Interest Expense 20,000 33,000 11,000 1,000 2,000 --
Interest Expense Non Operating 20,000 33,000 11,000 1,000 2,000 --
Interest Income 21,000 9,000 33,000 -- 37,000 16,000
Interest Income Non Operating 21,000 9,000 33,000 -- 37,000 16,000
Net Interest Income 1,000 -24,000 22,000 3,000 35,000 --
Pretax Income -1.5M -1.8M -1.7M -1.5M -1.2M --
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00 0.00 --
Net Income From Continuing And Discontinued Operation -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Income From Continuing Operation Net Minority Interest -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Income Including Noncontrolling Interests -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Income Common Stockholders -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Income -1.5M -1.8M -1.7M -1.5M -1.2M --
EBITDA -1.4M -1.8M -1.6M -1.5M -1.2M --
Normalized EBITDA -1.4M -1.8M -1.6M -1.5M -1.2M --
Reconciled Depreciation 47,000 42,000 43,000 39,000 18,000 --
Basic EPS -0.02 -0.02 -0.02 -- -0.02 -0.02
Diluted EPS -0.02 -0.02 -0.02 -- -0.02 -0.02
Basic Average Shares 77.6M 76.0M 73.6M -- 63.5M 61.5M
Diluted Average Shares 77.6M 76.0M 73.6M -- 63.5M 61.5M
Tax Rate For Calcs 0.00 0.00 0.00 0.00 0.00 --
Normalized Income -1.5M -1.8M -1.7M -1.5M -1.2M --
Diluted NI Availto Com Stockholders -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Income Continuous Operations -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Non Operating Interest Income Expense 1,000 -24,000 22,000 3,000 35,000 --
Other Gand A 763,000 1.1M 1.1M -613,000 782,000 --
Total Expenses 1.5M 1.8M 1.7M 1.5M 1.3M --
Total Operating Income As Reported -1.5M -1.8M -1.7M -1.5M -1.3M --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Cash And Cash Equivalents 983,000 1.2M 588,000 700,000 2.5M --
Cash Cash Equivalents And Short Term Investments 983,000 1.2M 588,000 700,000 2.5M --
Cash Equivalents -- -- -- 139,000 -- --
Cash Financial -- -- -- 561,000 -- --
Receivables 122,000 84,000 135,000 127,000 259,000 --
Prepaid Assets 0.00 600,000 600,000 766,000 -- --
Current Assets 1.1M 2.0M 1.4M 1.6M 2.8M --
Gross PPE 882,000 911,000 776,000 878,000 791,000 --
Accumulated Depreciation -- -- -- -71,000 -- --
Net PPE 882,000 911,000 776,000 807,000 791,000 --
Other Non Current Assets 618,000 -- -- -- -- --
Total Non Current Assets 1.5M 911,000 776,000 807,000 791,000 --
Total Assets 2.6M 2.9M 2.1M 2.4M 3.6M --
Current Debt And Capital Lease Obligation -- -- -- 2,000 -- --
Payables 496,000 678,000 366,000 57,000 263,000 --
Payables And Accrued Expenses 862,000 1.0M 553,000 396,000 435,000 --
Current Accrued Expenses 366,000 329,000 187,000 339,000 172,000 --
Current Deferred Revenue -- -- -- 0.00 0.00 2,000
Current Liabilities 862,000 1.0M 553,000 398,000 435,000 --
Long Term Debt And Capital Lease Obligation 79,000 91,000 31,000 31,000 31,000 --
Long Term Capital Lease Obligation 79,000 91,000 31,000 31,000 31,000 --
Total Non Current Liabilities Net Minority Interest 327,000 325,000 271,000 282,000 251,000 --
Total Liabilities Net Minority Interest 1.2M 1.3M 824,000 680,000 686,000 --
Common Stock 0.00 0.00 0.00 0.00 0.00 --
Capital Stock 0.00 0.00 0.00 0.00 0.00 --
Additional Paid In Capital 23.8M 22.8M 20.4M 19.5M 17.8M --
Retained Earnings -24.1M -22.6M -20.8M -19.1M -17.6M --
Gains Losses Not Affecting Retained Earnings -45,000 -46,000 -218,000 -202,000 -109,000 --
Common Stock Equity 1.5M 1.5M 1.3M 1.8M 2.9M --
Stockholders Equity 1.5M 1.5M 1.3M 1.8M 2.9M --
Total Equity Gross Minority Interest 1.5M 1.5M 1.3M 1.8M 2.9M --
Total Capitalization 1.5M 1.5M 1.3M 1.8M 2.9M --
Net Tangible Assets 1.5M 1.5M 1.3M 1.8M 2.9M --
Tangible Book Value 1.5M 1.5M 1.3M 1.8M 2.9M --
Working Capital 284,000 946,000 811,000 1.2M 2.4M --
Invested Capital 1.5M 1.5M 1.3M 1.8M 2.9M --
Total Debt 79,000 91,000 31,000 33,000 31,000 --
Share Issued 82.5M 74.5M 74.5M 71.1M 70.5M --
Ordinary Shares Number 82.5M 74.5M 74.5M 71.1M 70.5M --
Capital Lease Obligations 79,000 91,000 31,000 33,000 31,000 --
Current Capital Lease Obligation -- -- -- 2,000 -- --
Current Deferred Liabilities -- -- -- 0.00 0.00 2,000
Foreign Currency Translation Adjustments -45,000 -46,000 -218,000 -202,000 -109,000 --
Leases -- -- -- 348,000 -- --
Machinery Furniture Equipment -- -- -- 493,000 -- --
Non Current Deferred Liabilities 205,000 198,000 184,000 173,000 149,000 --
Non Current Deferred Revenue 205,000 198,000 184,000 173,000 149,000 --
Other Equity Interest 1.8M 1.4M 1.9M 1.6M 2.8M --
Other Payable 496,000 678,000 366,000 57,000 263,000 --
Other Properties 882,000 911,000 776,000 37,000 791,000 --
Other Receivables 122,000 84,000 135,000 3,000 259,000 --
Properties -- -- -- 0.00 -- --
Restricted Cash 41,000 41,000 41,000 41,000 41,000 --
Taxes Receivable -- -- -- 124,000 -- --
Tradeand Other Payables Non Current 43,000 36,000 56,000 78,000 71,000 --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024 Q2 2024Jun 30, 2024
Operating Cash Flow -1.3M -1.1M -986,000 -1.7M -818,000 --
Cash Flow From Continuing Operating Activities -1.3M -1.1M -986,000 -1.7M -818,000 --
Depreciation And Amortization 47,000 42,000 43,000 39,000 18,000 --
Depreciation Amortization Depletion 47,000 42,000 43,000 39,000 18,000 --
Stock Based Compensation 319,000 299,000 336,000 309,000 302,000 --
Change In Working Capital -195,000 424,000 336,000 -561,000 98,000 --
Change In Receivables -37,000 57,000 161,000 1,000 99,000 --
Change In Payables And Accrued Expense 18,000 229,000 155,000 41,000 -167,000 --
Change In Payable -161,000 229,000 155,000 41,000 -37,000 --
Change In Other Working Capital 21,000 138,000 20,000 -3,000 36,000 --
Change In Other Current Liabilities -- -- 0.00 -- -- --
Other Non Cash Items 10,000 14,000 -23,000 24,000 14,000 --
Capital Expenditure -12,000 -2,000 -32,000 -46,000 -301,000 --
Purchase Of PPE -12,000 -2,000 -32,000 -46,000 -301,000 --
Net PPE Purchase And Sale -12,000 -2,000 -32,000 -46,000 -301,000 --
Investing Cash Flow -12,000 -2,000 -32,000 -45,000 -301,000 --
Cash Flow From Continuing Investing Activities -12,000 -2,000 -32,000 -45,000 -301,000 --
Repayment Of Debt -8,000 -1,000 -3,000 -7,000 -8,000 --
Net Issuance Payments Of Debt -8,000 -1,000 -3,000 -7,000 -8,000 --
Issuance Of Capital Stock 998,000 1.6M 310,000 1.4M -157,000 --
Net Common Stock Issuance 998,000 1.6M 310,000 1.4M -157,000 --
Financing Cash Flow 1.1M 1.6M 910,000 177,000 1.3M --
Cash Flow From Continuing Financing Activities 1.1M 1.6M 910,000 177,000 1.3M --
Effect Of Exchange Rate Changes -11,000 119,000 -4,000 -220,000 -2,000 --
Changes In Cash -234,000 521,000 -108,000 -1.6M 140,000 --
Beginning Cash Position 1.2M 588,000 700,000 2.5M 2.4M --
End Cash Position 983,000 1.2M 588,000 700,000 2.5M --
Free Cash Flow -1.3M -1.1M -1.0M -1.8M -1.1M --
Common Stock Issuance 998,000 1.6M 310,000 1.4M -157,000 --
Long Term Debt Payments -8,000 -1,000 -3,000 -7,000 -8,000 --
Net Income From Continuing Operations -1.5M -1.8M -1.7M -1.5M -1.2M --
Net Long Term Debt Issuance -8,000 -1,000 -3,000 -7,000 -8,000 --
Net Other Financing Charges -- -- -- 21,000 14,000 --
Net Other Investing Changes -- -- -- 1,000 0.00 --
Proceeds From Stock Option Exercised 72,000 0.00 603,000 -1.2M 1.4M --
NEWS
Loading news...
TRENDING
Loading...